Japan’s Drug Maker M&A Activity Expected To Continue Record Pace
This article was originally published in PharmAsia News
Executive Summary
The already recording-setting mergers and acquisitions by Japanese companies, including drug makers, is expected to continue as others seek to add to foreign holdings. The companies of the second-largest economy in the world are expected to take advantage of the credit crisis around the world, according to industry insiders. Together, Japanese firms so far this year have made acquisitions worth a combined $47.1 billion, well over the previous record covering all of 2006. Besides Japanese pharmas, makers of auto parts and financial firms are expected to lead the M&A activity. (Click here for more
You may also be interested in...
Mark Cuban ‘Very Involved’, Insists Generics Company CEO
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
Bharat Biotech To Make GSK’s Malaria Vaccine For WHO
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Irish Ad Code Covers OTC Devices And Herbals For First Time
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.
Need a specific report? 1000+ reports available
Buy Reports